MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) is developing an AI-powered voice analysis platform designed to rapidly detect drug and alcohol impairment from short speech samples, offering a non-invasive alternative to traditional breath, saliva, urine and laboratory-based testing. The technology, trained on more than 50 million data points and analyzing over 140 acoustic markers, aims to deliver real-time impairment assessments through Edge AI kiosks, with initial field testing planned in 2026.
The company's initial commercial focus is on South American mining operations, where large-scale workforce screening presents significant safety and logistical challenges. As the global alcohol and drug testing devices market is projected to grow from approximately $2.5 billion in 2025 to $4.2 billion by 2033, MindBio sees opportunities to expand its platform into aviation, construction, transportation, law enforcement, call centers and healthcare. The company is leveraging its proprietary research to address the increasing demand for faster, scalable workplace impairment detection.
According to the company, the AI prediction model uses over 50 million data points to predict alcohol intoxication with remarkable accuracy, just by using the human voice. The enterprise platform includes Edge-AI kiosks integrating bespoke hardware and software for the detection of drug and alcohol intoxication using the human voice and AI in a range of enterprise environments. For more details on the technology, visit the full article at https://ibn.fm/Gw5Fa.
MindBio is a biotechnology company that is commercialising AI prediction technologies for drug and alcohol intoxication detection via voice analysis. The company's latest news and updates are available in the newsroom at https://ibn.fm/MBQIF.
